Our study aims to assess the validity of thrombotic biomarkers in estimation of venous thrombosis risk in cervical cancer patients.
A total of 134 cervical cancer patients treated in our hospital from September 2016 to November 2017 were selected. Coagulation markers were assayed using Sysmex CA 7000 and HISCL 5000. Baseline demographic and clinical data was then tracked.
The levels of plasmin inhibitor-plasmin complex (PIC), thrombin-antithrombin complex (TAT), and D-dimer (DD) were higher in the venous thrombosis positive subgroup, and the increase in levels of PIC, TAT, and DD appears to increase according to their cumulative risk score. Spearman’s analysis showed: There was significant positive correlation between the Padua score and the levels of PIC and DD (r = 0.459, 0.488).
Generally, studies have confirmed that the levels of PIC and DD may be useful for identifying cervical cancer patients at particularly high risk of thrombosis. Cervical cancer patients who are older, post menopause, receiving surgery or chemotherapy appear to be susceptible to venous thrombosis.